AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine
Description: One 28-day cycle = 100 mg/m\^2 orally on days 2-8.
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: One 28-day cycle = 100 mg/m\^2 orally on days 2-8.
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
Study NCT01399372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.
Study NCT01399372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose whole-brain radiation therapy
Description: Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
Study NCT03470844 — intervention group
Intervention type: BEHAVIORAL
Intervention: Face-to-face neurocognitive tests
Description: Assessment of attention, processing speed, working memory and executive function
Study NCT03470844 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychological screening
Description: Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
Study NCT03470844 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: Brain volume, chemical markers, functional outcome
Study NCT03470844 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Self-Assessment data
Description: EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
Study NCT02569749 — intervention group
Intervention type: OTHER
Intervention: Berlin and Epworth questionaries
Study NCT02569749 — intervention group
Intervention type: OTHER
Intervention: Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.
Study NCT02569749 — intervention group
Intervention type: OTHER
Intervention: Night polygraph / Polysomnography
Study NCT03098732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetically Enhanced Diffusion (MED)
Description: Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
Study NCT03098732 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MED Workstation Magnet Sham Control
Description: Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
Study NCT02905227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-427 (zolmitriptan inhalation powder)
Description: Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
Study NCT02617472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic floor exerciser
Description: Daily exercise using the study device
Study NCT02446119 — intervention group
Intervention type: DEVICE
Intervention: EndoFLIP
Description: Measurement of pyloric resistance and compliance
Study NCT04670367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk 30mins
Description: aerobic exercise
Study NCT04670367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk plus Baduanjin
Description: Walk 30mins then Baduanjin 12mins per day, 5 times per week.
Study NCT04670367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: routine care
Study NCT04670367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin
Description: Baduanjin exercise is moderate in intensity and short in duration (a set of Baduanjin takes about 12 minutes). Baduanjin consists of the sitting and standing practicing form. The sitting Baduanjin exercise conforms to the aspects of low-intensity and long-term aerobic activity, which is suitable for the rehabilitation training of patients who are in stable condition during hospitalization. The standing Baduanjin is more suitable for patients with sequential rehabilitation after discharge and can be adjusted based on the patient's condition
Study NCT00663182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5 mg/d
Study NCT01421719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystoscopic injection of Botox into the urinary bladder
Description: 100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
Study NCT00999778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver-Mediated Intervention
Description: 1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
Study NCT00999778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver-Education Intervention
Description: The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
Study NCT04405453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trapezius muscle injection
Description: TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval.
Study NCT04405453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive
Study NCT01773759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention child care programs
Description: Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
Study NCT03823313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCAI (Spiritual Care Assessment and Intervention)
Description: 4 sessions completed with an IU Health chaplain using a framework of questions called the Spiritual Care Assessment And Intervention tool. The weekly sessions will focus on one of the 4 areas of spiritual experience (meaning and purpose, relationships, transcendence and peace, self-worth and identity)
Study NCT02981615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
Study NCT02981615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
Study NCT02780128 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Needle or incisional tumor biopsy
Study NCT02780128 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Next Generation Sequencing
Description: Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
Study NCT02780128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Scans
Description: Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
Study NCT02780128 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor Scans
Description: Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
Study NCT02780128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow Tests
Description: Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exam
Description: The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Exam
Description: The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Exam
Description: Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labs
Description: Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Labs
Description: Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnancy Test
Description: If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pregnancy Test
Description: If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
Study NCT02780128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviews
Description: A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
Study NCT02780128 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interviews
Description: A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG
Description: This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
Study NCT02780128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
Study NCT02780128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
Study NCT02780128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
Study NCT02692638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early laparoscopic enterolysis
Description: The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
Study NCT02692638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nonoperative management
Description: Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
Study NCT03227640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stripping technique
Description: The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
Study NCT03227640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser (AcuPulse Duo, Lumenis)
Description: The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
Study NCT01898260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrafilcon B contact lens
Description: Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
Study NCT01898260 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lens
Description: Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
Study NCT02871752 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion
Description: mindfulness-based stress reduction
Study NCT02871752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion
Description: mindfulness-based stress reduction
Study NCT03124342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VANDERBILT ICU RECOVERY PROGRAM
Description: 10-component ICU Recovery Program intervention, including:~1. Nurse Practitioner In-Person Visit at the time of transfer from the ICU~2. Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~3. Performance of formal medication reconciliation at the time of transfer from the ICU~4. Access to a dedicated 24-hour a day, 7-day a week contact line~5. ICU Recovery Clinic Visit Medical Examination.~6. ICU Recovery Clinic Medication Reconciliation and Counseling~7. ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~8. ICU Recovery Clinic Case Management. A brief case management consultation~9. ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~10. Directed Subspecialty Referrals
Study NCT00785642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
Study NCT00156676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill
Study NCT00156676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Study NCT01171482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
Study NCT01171482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: 4mg/day IV push from day 1 to day 4 every 28 days
Study NCT01171482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: 400 mg BID every 28 days
Study NCT01069900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
Study NCT01069900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
Study NCT01069900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/Clavulanate
Description: Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
Study NCT01069900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
Study NCT01069900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem placebo
Description: Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
Study NCT01069900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate placebo
Description: Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
Study NCT00713167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (Vitagrape)
Description: Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months
Study NCT00713167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Grape Seed Extract
Description: Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months
Study NCT01429740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05180999
Description: Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
Study NCT01429740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution or capsules
Study NCT00865410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrika Bupropion 150 mg Extended-Released Tablet
Description: A: Experimental Subjects received Abrika formulated products under fasting conditions
Study NCT00865410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Study NCT02386644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAMG-1 Immunoassay
Description: Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.